Influence of lovastatin on concentrations and composition of lipoprotein subfractions

Shuichi Nozaki; Gloria L Vega; Robert J. Haddox; Elizabeth T. Dolan; Scott M Grundy

doi:10.1016/0021-9150(90)90079-X

Influence of lovastatin on concentrations and composition of lipoprotein subfractions

Shuichi Nozaki, Gloria L Vega, Robert J. Haddox, Elizabeth T. Dolan, Scott M Grundy

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

The effects of lovastatin therapy on concentrations and compositions of lipoproteins were examined in 14 patients with heterozygous familial hypercholesterolemia. The drug lowered plasma levels of cholesterol in total plasma, very low density + intermediate density lipoproteins (VLDL + IDL) and low density lipoproteins (LDL) by 25%, 41%, and 41%, respectively. Plasma total apo B was decreased by 35%. Three VLDL subfractions - VLDL-1, VLDL-2, and VLDL-3 - of progressively higher density were examined. Lovastatin therapy reduced only the heaviest - VLDL-3. Concentrations of VLDL-1 and VLDL-2 were unchanged. Total VLDL-cholesterol/apo B was reduced significantly. Drug therapy also altered the composition of LDL as shown by decreasing the cholesterol/apo B. Finally, lovastatin significantly raised HDL-cholesterol concentrations. This study showed that lovastatin modifies the composition of the major apo B-containing lipoproteins as well as reducing their concentrations.

Original language	English (US)
Pages (from-to)	101-110
Number of pages	10
Journal	Atherosclerosis
Volume	84
Issue number	2-3
DOIs	https://doi.org/10.1016/0021-9150(90)90079-X
State	Published - Oct 1990

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/0021-9150(90)90079-X

Cite this

@article{570898b70c064f92988214a709fdd6ae,

title = "Influence of lovastatin on concentrations and composition of lipoprotein subfractions",

abstract = "The effects of lovastatin therapy on concentrations and compositions of lipoproteins were examined in 14 patients with heterozygous familial hypercholesterolemia. The drug lowered plasma levels of cholesterol in total plasma, very low density + intermediate density lipoproteins (VLDL + IDL) and low density lipoproteins (LDL) by 25%, 41%, and 41%, respectively. Plasma total apo B was decreased by 35%. Three VLDL subfractions - VLDL-1, VLDL-2, and VLDL-3 - of progressively higher density were examined. Lovastatin therapy reduced only the heaviest - VLDL-3. Concentrations of VLDL-1 and VLDL-2 were unchanged. Total VLDL-cholesterol/apo B was reduced significantly. Drug therapy also altered the composition of LDL as shown by decreasing the cholesterol/apo B. Finally, lovastatin significantly raised HDL-cholesterol concentrations. This study showed that lovastatin modifies the composition of the major apo B-containing lipoproteins as well as reducing their concentrations.",

author = "Shuichi Nozaki and Vega, {Gloria L} and Haddox, {Robert J.} and Dolan, {Elizabeth T.} and Grundy, {Scott M}",

note = "Funding Information: The authors wish to thank Biman Pramanik, Carolyn Croy, Peggy Loessberg, Mahrooz Kha-demazad, Cindy Stenoien, and Majorie Whelan for their excellent technical assistance. The participation of the nursing and dietetic staffs of the metabolic unit of the Veterans Administration Medical Center and the General Clinical Research Center is gratefully acknowledged. This research was supported by the Veterans Administration, Grant HL-29252 and MO-IRR-00633 (NIH/ HDS/ DHHS), the Southwestern Medical Foundation, and the Moss Heart Foundation, Dallas, Texas.",

year = "1990",

month = oct,

doi = "10.1016/0021-9150(90)90079-X",

language = "English (US)",

volume = "84",

pages = "101--110",

journal = "Atherosclerosis",

issn = "0021-9150",

publisher = "Elsevier Ireland Ltd",

number = "2-3",

}

TY - JOUR

T1 - Influence of lovastatin on concentrations and composition of lipoprotein subfractions

AU - Nozaki, Shuichi

AU - Vega, Gloria L

AU - Haddox, Robert J.

AU - Dolan, Elizabeth T.

AU - Grundy, Scott M

N1 - Funding Information: The authors wish to thank Biman Pramanik, Carolyn Croy, Peggy Loessberg, Mahrooz Kha-demazad, Cindy Stenoien, and Majorie Whelan for their excellent technical assistance. The participation of the nursing and dietetic staffs of the metabolic unit of the Veterans Administration Medical Center and the General Clinical Research Center is gratefully acknowledged. This research was supported by the Veterans Administration, Grant HL-29252 and MO-IRR-00633 (NIH/ HDS/ DHHS), the Southwestern Medical Foundation, and the Moss Heart Foundation, Dallas, Texas.

PY - 1990/10

Y1 - 1990/10

N2 - The effects of lovastatin therapy on concentrations and compositions of lipoproteins were examined in 14 patients with heterozygous familial hypercholesterolemia. The drug lowered plasma levels of cholesterol in total plasma, very low density + intermediate density lipoproteins (VLDL + IDL) and low density lipoproteins (LDL) by 25%, 41%, and 41%, respectively. Plasma total apo B was decreased by 35%. Three VLDL subfractions - VLDL-1, VLDL-2, and VLDL-3 - of progressively higher density were examined. Lovastatin therapy reduced only the heaviest - VLDL-3. Concentrations of VLDL-1 and VLDL-2 were unchanged. Total VLDL-cholesterol/apo B was reduced significantly. Drug therapy also altered the composition of LDL as shown by decreasing the cholesterol/apo B. Finally, lovastatin significantly raised HDL-cholesterol concentrations. This study showed that lovastatin modifies the composition of the major apo B-containing lipoproteins as well as reducing their concentrations.

AB - The effects of lovastatin therapy on concentrations and compositions of lipoproteins were examined in 14 patients with heterozygous familial hypercholesterolemia. The drug lowered plasma levels of cholesterol in total plasma, very low density + intermediate density lipoproteins (VLDL + IDL) and low density lipoproteins (LDL) by 25%, 41%, and 41%, respectively. Plasma total apo B was decreased by 35%. Three VLDL subfractions - VLDL-1, VLDL-2, and VLDL-3 - of progressively higher density were examined. Lovastatin therapy reduced only the heaviest - VLDL-3. Concentrations of VLDL-1 and VLDL-2 were unchanged. Total VLDL-cholesterol/apo B was reduced significantly. Drug therapy also altered the composition of LDL as shown by decreasing the cholesterol/apo B. Finally, lovastatin significantly raised HDL-cholesterol concentrations. This study showed that lovastatin modifies the composition of the major apo B-containing lipoproteins as well as reducing their concentrations.

UR - http://www.scopus.com/inward/record.url?scp=0025000460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025000460&partnerID=8YFLogxK

U2 - 10.1016/0021-9150(90)90079-X

DO - 10.1016/0021-9150(90)90079-X

M3 - Article

C2 - 2282090

AN - SCOPUS:0025000460

SN - 0021-9150

VL - 84

SP - 101

EP - 110

JO - Atherosclerosis

JF - Atherosclerosis

IS - 2-3

ER -

Influence of lovastatin on concentrations and composition of lipoprotein subfractions

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this